PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

PharmaLex strengthens its commercial organization

The appointment of Sébastien Schmitt will further consolidate
PharmaLex’s commercial offerings for our clients.

PharmaLex Group, a leading provider of specialized services for pharma, biotech and medical device industries worldwide, is pleased to welcome Sébastien Schmitt as a valuable addition to our senior management team.

Sébastien joins PharmaLex as Chief Commercial Officer where he will oversee all aspects of PharmaLex commercial activities, ensuring that our clients benefit from a truly integrated service offering.

Through his role, he will ensure that PharmaLex further strengthens the commercial fundamentals, strategy, operations and a team dynamic that will be designed to grow with our clients’ needs and provide the best possible solution globally and regionally. Besides this key focus, he will also develop the PharmaLex Swiss country organization as its Managing Director. His vast experience in sales and marketing and his solid track record in delivering tailored service solutions, especially to multi-national clients, will be a timely enrichment to our organization.

Sébastien joins PharmaLex following nearly a decade with ProductLife Group, where he headed the delivery and commercial organization.

“I am very excited to join a growing organization like PharmaLex”, explained Sébastien. “Their reputation as a leader in specialized services for the life science industry is well known and their global footprint presents excellent opportunities to provide real added value to their clients”, he commented.

“We are extremely pleased that Sébastien is joining us to head and further shape our commercial organisation. His ability to deliver customer-focused and results-oriented solutions was key during the selection process”, explained Dr. Thomas Dobmeyer, CEO PharmaLex. “Furthermore, we have seen a very positive development in the entire DACH region and strengthening our location in Switzerland will be of particular strategic importance, ensuring that our services can be expanded to the hotspot of the Swiss pharmaceutical industry.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026